- In September 2021, Merck & Co., Inc. and Acceleron Pharma Inc. have announced a definitive agreement whereby Merck, through a subsidiary, will acquire Acceleron for USD 180 per share in cash, totaling approximately USD 11.5 billion in equity value. This acquisition will enable Merck to enhance its pipeline with Acceleron's innovative therapies, strengthening its position in the biopharmaceutical market and expanding its capabilities in treating rare diseases
- In March 2021, Thermo Fisher Scientific Inc. launched the new Gibco Human Plasma-like Medium (HPLM), the first cell culture medium on the market that mimics the metabolic profile of human plasma that is designed to provide researchers with a realistic view of cell growth within the human body
